Welcome to our dedicated page for Kineta SEC filings (Ticker: KA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kineta Inc. filings document the corporate transition of a clinical-stage oncology biotechnology issuer whose common stock was formerly registered under the Exchange Act. The record includes material-event reporting on stockholder voting for merger-related proposals and proxy disclosures tied to the company's capital structure, governance and transaction approvals.
The Form 15 filed by Kineta, LLC, as successor by merger to Kineta, Inc., records the termination of registration or suspension of reporting duties for Kineta common stock following the June 30, 2025 mergers that left Kineta, LLC as a wholly owned subsidiary of TuHURA Biosciences. Other disclosure categories include material agreements, proxy materials, shareholder voting matters, governance, capital-structure and registration-status disclosures.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,823,138 shares of Kineta, Inc. common stock. The filing shows the reporting persons have shared voting and dispositive power over 1,823,138 shares and no sole voting or dispositive power. The cover tables list the percentage of the class as 3.64%, while Item 4(b) later reports the percentage as 12.84% and states the percentage is based on 1,823,138 shares outstanding as of March 28, 2025. The statement explains Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Steven Boyd is the managing member of Armistice Capital. The Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement.